Notes
from approximately 11 000 patients in clinical trials, and 27 000 patients in the postmarketing setting.
Reference
Health Canada. KEYTRUDA (pembrolizumab) - Risk of Severe Skin Reactions: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Internet Document : 20 Mar 2017. Available from: URL: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/62670a-eng.php
Rights and permissions
About this article
Cite this article
Severe skin reactions with Keytruda: Canadian updates. Reactions Weekly 1645, 7 (2017). https://doi.org/10.1007/s40278-017-28089-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-017-28089-x